| 王燕,许培义,王宇.生长抑素联合奥美拉唑治疗维持性血液透析患者上消化道出血的临床效果[J].济宁医学院学报,2023,46(4):257-260 |
| 生长抑素联合奥美拉唑治疗维持性血液透析患者上消化道出血的临床效果 |
| Clinical effect of somatostatin combined with omeprazole on upper gastrointestinal bleeding in maintenance hemodialysis patients |
| 投稿时间：2022-12-04 |
| DOI：10.3969/j.issn.1000-9760.2023.04.007 |
| 中文关键词: 生长抑素;奥美拉唑;维持性血液透析;消化道出血 |
| 英文关键词: Somatostatin;Omeprazole;Maintenance hemodialysis;Gastrointestinal bleeding |
| 基金项目: |
| 作者 | 单位 | E-mail | | 王燕 | 滕州市中心人民医院血液透析室, 滕州 277599 | | | 许培义 | 滕州市中心人民医院药学部, 滕州 277599 | 827986766@qq.com | | 王宇 | 滕州市中心人民医院急诊科, 滕州 277599 | |
|
| 摘要点击次数: 603 |
| 全文下载次数: 569 |
| 中文摘要: |
| 目的 探讨维持性血液透析患者消化道出血应用生长抑素联合奥美拉唑治疗的临床效果。方法 选取2021年10月—2022年10月维持性血液透析患者因上消化道出血入住本院，96例，随机分2组，其中对照组单纯奥美拉唑治疗，观察组生长抑素联合奥美拉唑治疗，观察两组临床疗效。结果 观察组患者止血有效率为95.83%，高于对照组的81.25%，差异有统计学意义（χ2=5.031，P<0.05）。治疗后观察组患者红细胞比容为（27.35±2.68）%和血红蛋白为（92.68±9.87） g/L，分别高于治疗前的（19.95±2.63）%和（76.21±10.36） g/L，而且观察组患者治疗后的红细胞比容及血红蛋白水平分别高于对照组的（23.98±2.55）%和（85.64±9.35） g/L，差异有统计学意义（P<0.05）。观察组输血量为（1.42±0.51） U少于对照组的（2.07±0.65） U，观察组止血时间为（26.49±3.52） h短于对照组的（32.22±4.86） h，观察组住院时间为（5.26±1.34） d短于对照组的（6.42±1.85） d，差异有统计学意义（P<0.05）。观察组患者不良反应率8.33%，低于对照组的12.50%；观察组再出血率4.17%，低于对照组的22.92%，差异有统计学意义（P<0.05）。结论 维持性血液透析患者出现上消化道出血，生长抑素联合应用奥美拉唑能提升止血效果，防止再出血，同时减少不良反应，患者能更快康复出院，值得临床应用推广。 |
| 英文摘要: |
| Objective To investigate the clinical effect of somatostatin combined with omeprazole in the treatment of gastrointestinal bleeding in maintenance hemodialysis patients.Methods A total of 96 patients who participated in this study were patients undergoing maintenance hemodialysis in our hospital and were admitted for upper gastrointestinal bleeding from October 2021 to October 2022.The patients were randomly divided into two groups.The control group was treated with omeprazole alone, while the observation group was treated with somatostatin at the same time, and the clinical efficacy was compared.Results The effective rate of hemostasis in the observation group was 95.83%, which was significantly higher than 81.25% in the control group, and the difference was statistically significant (χ2=5.031, P<0.05).After treatment, the hematocrit[(27.35±2.68)%] and hemoglobin[(92.68±9.87)g/L] of patients in the two groups were higher than those before treatment[(19.95±2.63)% and (76.21±10.36)g/L].The hematocrit and hemoglobin levels of the observation group after treatment were higher than those of the control group[(23.98±2.68)% and (85.64±9.35)g/L], and the differences were statistically significant (P<0.05).The blood transfusion volume of the observation group[(1.42±0.51)U] was less than that of the control group[(2.07±0.65)U], the hemostasis time of the observation group[(26.49±3.52)h] was shorter than that of the control group[(32.22±4.86)h], and the hospitalization time of the observation group[(5.26±1.34)d] was shorter than that of the control group[(6.42±1.85)d]. The difference was statistically significant (P<0.05). The adverse reaction rate of the observation group was 8.33%, which was lower than 12.50% of the control group.The rebleeding rate of the observation group was 4.17%, which was lower than 22.92% of the control group, and the difference was statistically significant (P<0.05).Conclusion After maintenance hemodialysis patients with upper gastrointestinal bleeding, somatostatin and omeprazole combined application, can improve the hemostatic effect, prevent rebleeding, and reduce adverse reactions.This can make patients recover faster, and is worthy of clinical application and promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
|
|
|
